Osteoporosis – the silent epidemic of the 21st century
DOI:
https://doi.org/10.21164/pomjlifesci.1225Słowa kluczowe:
metabolic bone diseases, FRAX, RAXplus, DEXA, low-energy fracture, postmenopausal osteoporosis, BMDAbstrakt
Osteoporosis is the most prevalent bone tissue disorder worldwide. Its incidence is closely linked to the aging of the global population – a demographic shift observed since the late 19th century. The disease progresses asymptomatically, with the first clinical manifestation often being a low-energy fracture, which typically indicates an advanced stage of the condition. As a result, osteoporosis is frequently underestimated by both patients and healthcare professionals. The aim of this study was to analyze the available scientific literature indexed in databases such as PubMed, Google Scholar, and ScienceDirect. The article presents a historical overview, pathophysiology, epidemiology, diagnostic criteria, and risk factors associated with the disease. It also discusses current strategies for prevention and pharmacological treatment. Further research is essential to identify optimal diagnostic and therapeutic approaches and to elevate public awareness regarding the seriousness of osteoporosis.
Bibliografia
Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194(2):S3-11. doi: 10.1016/j.ajog.2005.08.047.
Janiszewska M, Kulik T, Dziedzic M, Żołnierczuk-Kieliszek D, Barańska A. Osteoporoza jako problem społeczny – patogeneza, objawy i czynniki ryzyka osteoporozy pomenopauzalnej. Probl Hig Epidemiol 2015:96(1):106-14.
Curate F. Osteoporosis and paleopathology: a review. J Anthropol Sci 2014;92:119-46. doi: 10.4436/JASS.92003.
Schapira D, Schapira C. Osteoporosis: the evolution of a scientific term. Osteoporos Int 1992;2(4):164-7. doi: 10.1007/BF01623921.
Bijlsma AY, Meskers CG, Westendorp RG, Maier AB. Chronology of age-related disease definitions: osteoporosis and sarcopenia. Ageing Res Rev 2012;11(2):320-4. doi: 10.1016/j.arr.2012.01.001.
Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50. doi: 10.1016/0002-9343(93)90218-e.
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. World Health Organization; 1994. https://iris.who.int/bitstream/handle/10665/39142/WHO_TRS_843_eng.pdf (24.08.2025).
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6);785-94. doi: 10.1001/jama.285.6.785.
Rajska-Neumann A. Osteoporoza – definicja, epidemiologia, rozpoznawanie, leczenie i profilaktyka. Farmacja Współczesna 2008;1:47-53.
Liang B, Burley G, Lin S, Shi YC. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell Mol Biol Lett 2022;27:72. doi: 10.1186/s11658-022-00371-3.
Siddiqui JA, Partridge NC. Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. Physiology (Bethesda) 2016;31(3):233-45. doi: 10.1152/physiol.00061.2014.
Bone Remodeling. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK499863/ (24.08.2025).
Hadjidakis DJ, Androulakis II. Bone Remodeling. Ann NY Acad Sci 2006;1092:385-96. doi: 10.1196/annals.1365.035.
Ansari N, Sims NA. The Cells of Bone and Their Interactions. Handb Exp Pharmacol 2020;262:1-25. doi: 10.1007/164_2019_343.
Liu L, Luo P, Wen P, Xu P. The role of magnesium in the pathogenesis of osteoporosis. Front Endocrinol 2024;15:1-11. doi: 10.3389/fendo.2024.1406248.
Al Saedi A, Stupka N, Duque G. Pathogenesis of Osteoporosis. Handb Exp Pharmacol 2020;262:353-67. doi: 10.1007/164_2020_358.
Smektała A, Dobosz A. Osteoporoza – patofizjologia, objawy, profilaktyka i leczenie. Farm Pol 2020;76 (6):344-52. doi: 10.32383/farmpol/125762.
Barszczewski K, Karaś R, Kępczyńska A, Górecki K, Lepich T. Osteoporoza starcza – poważny problem starzejącego się społeczeństwa. Gerontol Pol 2024;32:105-11.
Malachowski K, Materkowski M. Osteoporotic Fractures During and after Pandemic Time – Always Required Treatment. Approach of the Physician, Comments of the Professor. Ortop Traumatol Rehabil 2020;22(4):281-5. doi: 10.5604/01.3001.0014.4151.
Amarnath SS, Kumar V, Das SL. Classification of Osteoporosis. Indian J Orthop 2023;57(1):49-54. doi: 10.1007/s43465-023-01058-3.
Stromsnes K, Fajardo CM, Soto-Rodriguez S, Kajander ERU, Lupu RI, Pozo-Rodriguez M, et al. Osteoporosis: Causes, Mechanisms, Treatment and Prevention: Role of Dietary Compounds. Pharmaceuticals 2024;17:1697. doi: 10.3390/ph17121697.
Dhruvee P, Bhagawati S. Decoding osteoporosis: Understanding the disease, exploring current and new therapies and emerging targets. J Orthop Rep 2025;4(4):100472. doi: 10.1016/j.jorep.2024.100472.
Osteoporosis. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK441901/ (24.08.2025).
Shimazaki S, Sato J. Idiopathic Juvenile Osteoporosis: A Case Report and Literature Review. Cureus 2024;16(9):e68361. doi: 10.7759/cureus.68361.
Wade E, Mulholland K, Shaw I, Cundy T, Robertson S. Idiopathic juvenile osteoporosis-a polygenic disorder? JBMR Plus 2024;8(9):ziae099. doi: 10.1093/jbmrpl/ziae099.
Imerci A, Canbek U, Haghari S, Sürer L, Kocak M. Idiopathic juvenile osteoporosis: A case report and review of the literature. Int J Surg Case Rep 2015;9:127-9. doi: 10.1016/j.ijscr.2015.02.043.
Akhvlediani G, Nakaidze N, Dzodzuashvili E, Gabidzashvili N, Dopidze E, Mikaberidze A, et al. Idiopathic Juvenile Osteoporosis Diagnosed in Adulthood: The First Documented Case in Georgia. Cureus 2025;17(5):e83707. doi: 10.7759/cureus.83707.
The Epidemiology and Pathogenesis of Osteoporosis. Endotext. 2020. https://www.ncbi.nlm.nih.gov/books/NBK279134/ (24.08.2025).
Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 2021;16:609. doi: 10.1186/s13018-021-02772-0.
Wang L, Yu W, Yin X, Cui L, Tang S, Jiang N, et al. Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study. JAMA Netw Open 2021;4(8):e2121106. doi: 10.1001/jamanetworkopen.2021.21106.
Epidemiology of osteoporosis. Balloon Kyphoplasty. Springer; 2008. https://link.springer.com/chapter/10.1007/978-3-211-74221-1_1 (24.08.2025).
Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull 2020;133(1):105-17. doi: 10.1093/bmb/ldaa005.
Program polityki zdrowotnej profilaktyki i wczesnego wykrywania osteoporozy dla mieszkańców województwa wielkopolskiego na lata 2025–2026. Załącznik do Uchwały Zarządu Wojewódzwtwa Wielkopolskiego nr 1285/2025 z 29 stycznia 2025 r. https://bip.umww.pl/artykuly/2831947pliki/20250129123537_programprofilaktykiiwczesnegowykrywaniaosteoporozy.pdf (24.08.2025).
Fragility fractures. International Osteoporosis Foundation; 2025. https://www.osteoporosis.foundation/health-professionals/fragility-fractures/epidemiology (24.08.2025).
Kuczera W, Pluskiewicz W. Osteoporoza starcza. Ann Acad Med Siles 2012;66(6):57-65.
Marcinowska-Suchowierska E, Czerwiński E, Badurski J, Walicka M, Tałałaj M. Osteoporoza – diagnostyka i terapia u osób starszych. Postępy Nauk Medycznych 2011;24(5):410-23.
Głuszko P, Sewerynek E, Misiorowski W, Konstantynowicz J, Marcinowska-Suchowierska E, Blicharski T, et al. Zalecenia postępowania diagnostycznego i leczniczego w osteoporozie w Polsce. Aktualizacja 2022. Endokrynol Pol 2023;74(1). doi: 10.5603/EP.a2023.0012.
Ćwirlej-Sozańska A. Ocena ryzyka złamań osteoporotycznych. Prz Med Uniw Rzesz Inst Leków 2013;4:515-24.
Pusz-Sapa A, Sobczyk J. Gęstość tkanki kostnej młodych osób w zależności od aktywności fizycznej. Inżynier i Fizyk Medyczny 2022;11(3):253-9.
Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, et al. Osteoporosis Guidelines Committee. Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can 2006;28(2):95-112. doi: 10.1016/s1701-2163(16)32087-4.
Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest 2024;47(3):501-11. doi: 10.1007/s40618-023-02219-9.
Leszczyński P, Korkosz M, Pawlak-Buś K, Bykowska M, Gruszecka K, Górska A, et al. Diagnostyka i leczenie osteoporozy – zalecenia Polskiego Towarzystwa Reumatologicznego 2015. Forum Reumatol 2015;1(1):12-24.
Zerikly R, Demetriou EW. Use of Fracture Risk Assessment Tool in clinical practice and Fracture Risk Assessment Tool future directions. Womens Health 2024:17455057241231387. doi: 10.1177/17455057241231387.
Discover the advantages of FRAXplus. 2025. https://fraxplus.org/pl/frax-plus (24.08.2025).
Kim JY, Kong GM. Age- and Gender-Related Femoral Bowing Analysis in the Korean Population and Features for Clinical Applications. Med Kaunas 2024;60(12):1930. doi: 10.3390/medicina60121930.
Bijelic R, Milicevic S, Balaban J. Risk Factors for Osteoporosis in Postmenopausal Women. Med Arch 2017;71(1):25-8. doi: 10.5455/medarh.2017.71.25-28.
Ji W, Pan B, Chen X, Lao Z, Yang W, Qian Y. Mendelian randomization studies of risk and protective factors for osteoporosis: a systematic review and meta-analysis. Front Endocrinol 2025;15:1486188. doi: 10.3389/fendo.2024.1486188.
Pandey D, Basnet S, Pradhananga S, Shrestha S, Rijal B, Neupane A, et al. Prevalence and Risk Factors of Osteoporosis among Postmenopausal Women Visiting a District Hospital of Nepal: An Observational Study. J Nepal Med Assoc 2024;62(279):744-9. doi: 10.31729/jnma.8800.
Özmen S, Kurt S, Timur HT, Yavuz O, Kula H, Demir AY, et al. Prevalence and Risk Factors of Osteoporosis: A Cross-Sectional Study in a Tertiary Center. Med Kaunas 2024;60(12):2109. doi: 10.3390/medicina60122109.
Su W, Jia H, Yang L, Zhang J, Wei Z, Tsikwa P, et al. Risk factors for osteoporosis in elderly patients with type 2 diabetes: A protocol for systematic review and meta-analysis. PLoS One 2025;20(2):e0319602. doi: 10.1371/journal.pone.0319602.
Florez H, Carrasco JL, Barberá M, Hernández-Rodríguez J, Muxi A, Mocritcaia A. et al. Risk factors for glucocorticoid induced osteoporosis in young adults. Front Endocrinol 2025;16:1528962. doi: 10.3389/fendo.2025.1528962.
Kuang C, Shang J, Ma M, Huang S, Yan B, Zhong Y, et al. Risk factors and clinical prediction models for osteoporosis in pre-dialysis chronic kidney disease patients. Ren Fail 2024;46(2):2361802. doi: 10.1080/0886022X.2024.2361802.
Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 2019;104(3):235-8. doi: 10.1007/s00223-018-00512-x.
Weber-Rajek M, Ciechanowska K. Physical treatment in postmenopausal osteoporosis – A review of research. Ginekol Poloznictwo 2015;35(1):53-8.
Daly RM, Dalla Via J, Duckham RL, Fraser SF, Helge EW. Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription. Braz J Phys Ther 2019;23(2):170-80. doi: 10.1016/j.bjpt.2018.11.011.
Benedetti MG, Furlini G, Zati A, Letizia Mauro G. The Effectiveness of Physical Exercise on Bone Density in Osteoporotic Patients. Biomed Res Int 2018;2018:4840531. doi: 10.1155/2018/4840531.
Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. J Bone Miner Res 2018;33(2):211-20. doi: 10.1002/jbmr.3284.
Layne JE, Nelson ME. The effects of progressive resistance training on bone density: a review. Med Sci Sports Exercise 1999;31(1):25-30.
Rizzoli R, Biver E, Brennan-Speranza TC. Nutritional intake and bone health. Lancet Diabetes Endocrinol 2021;9(9):606-21. doi: 10.1016/S2213-8587(21)00119-4.
Mędrela-Kuder E, Bis H. Porównanie odżywiana kobiet z prawidłową i obniżoną masą kostną. Bromat Chem Toksykol 2011;44(3);415-9.
Muñoz-Garach A, García-Fontana B, Muñoz-Torres M. Nutrients and Dietary Patterns Related to Osteoporosis. Nutrients 2020;12(7):1986. doi: 10.3390/nu12071986.
Suplementy diety, czy potrzebujesz? Instytut Żywności i Żywienia. 2025. https://ncez.pzh.gov.pl/wp-content/uploads/2021/03/broszura_suplementy.pdf (24.08.2025).
Normy żywienia dla populacji Polski. Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy; 2025. https://ncez.pzh.gov.pl/wp-content/uploads/2025/02/Normy-zywienia-dla-populacji-Polski-07-2025-2.pdf (24.08.2025).
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2022;33(10):2049-102. doi: 10.1007/s00198-021-05900-y.
Gawryś J, Gawryś K, Doroszko A. Sezonowe zmiany stężenia witaminy D i ich wpływ na jej suplementację. Kosmetologia Estetyczna 2016;5(6):561-6.
Rizzoli R, Chevalley T. Nutrition and Osteoporosis Prevention. Curr Osteoporos Rep 2024;22(6):515-22. doi: 10.1007/s11914-024-00892-0.
Martiniakova M, Babikova M, Mondockova V, Blahova J, Kovacova V, Omelka R. The Role of Macronutrients, Micronutrients and Flavonoid Polyphenols in the Prevention and Treatment of Osteoporosis. Nutrients 2022;14(3):523. doi: 10.3390/nu14030523.
Papadopoulou SK, Papadimitriou K, Voulgaridou G, Georgaki E, Tsotidou E, Zantidou O, et al. Exercise and Nutrition Impact on Osteoporosis and Sarcopenia-The Incidence of Osteosarcopenia: A Narrative Review. Nutrients 2021;13(12):4499. doi: 10.3390/nu13124499.
Niezłomne warszawianki. Profilaktyka osteoporozy wśród seniorek. Zdrowie. Miasto Stołeczne Warszawa. 2025. https://zdrowie.um.warszawa.pl/niezlomne-warszawianki (1.10.2025).
Program polityki zdrowotnej w zakresie profilaktyki i wczesnego wykrywania osteoporozy wśród mieszkańców województwa mazowieckiego na lata 2024–2026. Urząd Marszałkowski Województwa Mazowieckiego w Warszawie. 2025. https://mazovia.pl/pl/bip/zalatw-sprawe/zdrowie-i-polityka-spoleczna/priorytetowe-dzialania-w-obszarze-zdrowia/programy-polityki-zdrowotnej/program-polityki-zdrowotnej-w-zakresie-profilaktyki-i-wczesnego-wykrywania-osteoporozy-wsrod-mieszkancow-wojewodztwa-mazowieckiego-na-lata-2024-2026.html (1.10.2025).
Brown JP. Long-Term Treatment of Postmenopausal Osteoporosis. Endocrinol Metab 2021;36(3):544-52. doi: 10.3803/EnM.2021.301.
Głuszko P. Osteoporoza. Reumatologia 2016;(1):124-8. doi: 10.5114/reum.2016.60014.
Vandenbroucke A, Luyten FP, Flamaing J, Gielen E. Pharmacological treatment of osteoporosis in the oldest old. Clin Interv Aging 2017;12:1065-77. doi: 10.2147/CIA.S131023.
Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019;30(1):3-44. doi: 10.1007/s00198-018-4704-5.
Amin U, McPartland A, O’Sullivan M, Silke C. An overview of the management of osteoporosis in the aging female population. Womens Health 2023;19:17455057231176655. doi: 10.1177/17455057231176655.
Bisphosphonate. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK470248/ (24.08.2025).
Hayes KN, Winter EM, Cadarette SM, Burden AM. Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making. J Clin Med 2021;10(5):1140. doi: 10.3390/jcm10051140.
Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 2013;5(3):107-11. doi: 10.1177/1759720X13477714.
Gehrke B, Alves Coelho MC, Brasil d’Alva C, Madeira M. Long-term consequences of osteoporosis therapy with bisphosphonates. Arch Endocrinol Metab 2023;68:e220334. doi: 10.20945/2359-4292-2022-0334.
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019;104(5):1595-622. doi: 10.1210/jc.2019-00221.
8Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab 2016;101(8):3163-70. doi: 10.1210/jc.2016-1801.
Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther 2022;39(1):58-74. doi: 10.1007/s12325-021-01936-y.
McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 2017;28(5):1723-32. doi: 10.1007/s00198-017-3919-1.
Denosumab. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK535388/ (24.08.2025).
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5.
Teriparatide. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK559248/ (24.08.2025).
Blick SKA, Dhillon S, Keam SJ. Teriparatide. Drugs 2008;68:2709-37. doi: 10.2165/0003495-200868180-00012.
Hauser B, Alonso N, Riches PL. Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups. J Clin Med 2021;10(7):1403. doi: 10.3390/jcm10071403.
Raloxifene. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK544233/ (24.08.2025).
Hansdóttir H. Raloxifene for older women: a review of the literature. Clin Interv Aging 2008;3(1):45-50. doi: 10.2147/cia.s224.
Ma HY, Chen S, Lu LL, Gong W, Zhang AH. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis. Horm Metab Res 2021;53(11):730-7. doi: 10.1055/a-1655-4362.
Khairallah P, Nickolas TL. Effectiveness of Pharmacological Interventions for Treatment of Osteoporosis in Patients With CKD 3-5D: No Clear Choices. Am J Kidney Dis 2022;80(6):797-800. doi: 10.1053/j.ajkd.2022.08.002.
Nitta K, Yajima A, Tsuchiya K. Management of Osteoporosis in Chronic Kidney Disease. Intern Med 2017;56(24):3271-6. doi: 10.2169/internalmedicine.8618-16.
Haghverdi F, Farbodara T, Mortaji S, Soltani P, Saidi N. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J Kidney Dis 2014;8(6):461-6.
Kukowka A, Pluskota M, Arciszewski M, Sroczyński T. Obecna farmakoterapia osteoporozy oraz jej przyszłość. Farm Pol 2021;77(11):683-9. doi: 10.32383/farmpol/145401.
Pobrania
Opublikowane
Numer
Dział
Licencja
Prawa autorskie (c) 2026 Maksymilian Dobosz, Wiktoria Ficoń, Beata Całyniuk
Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Autor pozostaje właścicielem praw autorskich i praw pokrewnych – udziela jedynie nieodpłatnej licencji na udostępnianie pracy zgodnie z licencją Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 3.0 PL (CC BY-NC-ND 3.0 PL).
